课题基金 / 基金详情

Nano-cocktail overcomes multidrug-resistance for ovarian cancer therapy

Nano-cocktail overcomes multidrug-resistance for ovarian cancer therapy
纳米鸡尾酒克服了卵巢癌治疗的多重耐药性
批准号:
8958102
负责人:
Peisheng Xu
金额:
$36.63万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-07-01 至 2019-06-30
关键词:
2-methoxyestradiolAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsArtsBindingBiodistributionBiomedical EngineeringBiomedical ResearchCancer EtiologyCell ProliferationCellsCessation of lifeChemistryChemotherapy-Oncologic ProcedureClinical TrialsDeath RateDevelopmentDiagnosisDiseaseDoctor of PharmacyDoxorubicinDrug CarriersDrug CombinationsDrug KineticsDrug resistanceERBB2 geneEncapsulatedEnsureEnvironmentEquipmentExhibitsGynecologicHead and Neck NeoplasmsKineticsLaboratoriesLigandsMalignant NeoplasmsMalignant neoplasm of ovaryMinnesotaMinorityModelingModificationMonitorMulti-Drug ResistanceMusNanoGelNatureNeoplasm MetastasisNormal CellOperative Surgical ProceduresOxidation-ReductionPaclitaxelPatientsPharmaceutical PreparationsPharmacologic SubstancePharmacy StudentsPolymersProgram ReviewsPropertyRecruitment ActivityRegimenRelapseResearchResearch TrainingResistanceScienceScientistSerumSolid NeoplasmSouth CarolinaStagingStudentsSurvival RateSystemTherapeutic EffectThinkingToxic effectTrainingTumor DebulkingTumor TissueUnited StatesUniversitiesWomanXenograft ModelXenograft procedureantitumor effectbasecancer cellcancer stem cellcancer therapychemotherapycollegedensityeffective therapyexperiencefemale reproductive systemfight againstgraduate studentimprovedintraperitonealkillingsmortalitymouse modelnanonanoparticlenanoparticulatenext generationnovelovarian neoplasmprogramspublic health relevancereceptorresponsesigma-2 receptorskillssubcutaneoussuccesstooltreatment strategytumortumor growthundergraduate studentunderrepresented minority student

项目摘要

项目成果

Peisheng Xu的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
 DESCRIPTION (provided by applicant): Ovarian cancer is the fifth most common cause of cancer-related deaths in women and results in more deaths than any other cancer of the female reproductive system. The primary reasons for the high death rate of ovarian cancer are multidrug-resistance and the metastatic nature of cancer stem cells (CSCs). Since conventional anticancer drugs cannot kill drug resistant cells and eliminate CSCs, a novel effective treatment for ovarian cancer is urgently needed. The objective of this research is to develop a dual targeted nano-cocktail (DTNC) for safe and effective ovarian cancer therapy. We hypothesize that: (a) the low density combination of two targeting moieties can minimize the non-specific targeting effect while ensuring that the drug carrier will be exclusively localized in the tumor tissue and taken up by cancer cells through hetero-multivalent binding; (b) the drug combination of different anticancer mechanisms will exhibit synergistic effects and eradicate ovarian tumor. Our project has three specific aims. In Aim 1, we will explore drug combinations for optimal cancer cell proliferation inhibitory effect. Aim 2 will examine the dual-ligand targeting effect on the biodistribution of DTNC and investigate its pharmacokinetic properties. Aim 3 will evaluate the tumor growth inhibitory effect of DTNC in both subcutaneous xenograft and orthotopic intraperitoneal tumor mouse models and examine its systemic toxicity. Over the course of this 3-year project, undergraduate, graduate, and Doctor of Pharmacy students will participate in the project in various levels, from hands-on skills with state-of-arts equipment to creative thinking. Undergraduate students will be recruited from the highly selective Honors College and Biomedical Engineering program of the University of South Carolina, as well as Morris College, a Historically Black, coeducational college. Therefore, the development of DTNC will provide clinicians with a more effective tool in fighting against ovarian cancer as well as offer precious biomedical research training opportunities for students, especially underrepresented minority students.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cancer cell selective killing nanoparticle for advanced ovarian cancer treatment
Cancer cell selective killing nanoparticle for advanced ovarian cancer treatment
The development of a multifunctional nanoenzyme for AD treatment
  • 批准号:
    10611675
  • 项目类别:
  • 资助金额:
    $29.96万
  • 财政年份:
    2022
  • 负责人:
    Peisheng Xu
  • 依托单位:
Brain targeted nanoparticle for Alzheimer's disease therapy
海外基金